Photodynamic therapy reduces the histological features of actinic damage and the expression of early oncogenic markers
Summary Background Photodynamic therapy (PDT) has been shown to be effective in treating nonmelanoma skin cancer (NMSC), especially actinic keratosis (AK). Moreover, there is sufficient evidence of its effectiveness in preventing the appearance of premalignant and malignant lesions in organ transpl...
Gespeichert in:
Veröffentlicht in: | British journal of dermatology (1951) 2011-07, Vol.165 (1), p.144-151 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 151 |
---|---|
container_issue | 1 |
container_start_page | 144 |
container_title | British journal of dermatology (1951) |
container_volume | 165 |
creator | Bagazgoitia, L. Cuevas Santos, J. Juarranz, Á. Jaén, P. |
description | Summary
Background Photodynamic therapy (PDT) has been shown to be effective in treating nonmelanoma skin cancer (NMSC), especially actinic keratosis (AK). Moreover, there is sufficient evidence of its effectiveness in preventing the appearance of premalignant and malignant lesions in organ transplant recipients.
Objectives To describe the molecular and genetic changes underlying this preventive effect.
Methods Twenty‐two patients with AK were treated with methyl aminolaevulinate and red light. Biopsies were performed before and 6 weeks after the treatment. Conventional histopathology and immunohistochemistry were carried out.
Results Not only was a reduction in the dysplasia and elastosis observed, but also a decreased expression of Ki‐67 and p53. The abnormal findings did not disappear completely in all cases. The expression of cyclin D1 remained stable.
Conclusions These findings show that PDT has the potential to reduce the histological signs of photoageing. Moreover, the reduction of Ki‐67, a marker of proliferation and of p53, a marker of early skin carcinogenesis, indicates a reversal of the carcinogenic process. On the other hand, the fact that one treatment does not clear dysplasia and expression of p53 completely, and the persistence of cyclin D1, indicate that one single treatment, despite showing good clinical results, is not sufficient to clear completely the signs of chronic actinic damage, and thus the risk of NMSC. |
doi_str_mv | 10.1111/j.1365-2133.2011.10270.x |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_907161932</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>907161932</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4200-f3daa682a3d03c78a053f139fe373ed8cabfeee65899bfb8adfa272ff596e1f93</originalsourceid><addsrcrecordid>eNpFkU-P0zAQxS0EYrsLXwHlgjgljD3NvwsS7LILaAVIgDhaU2fcpiRxN06g-fY4bSm-2Nb7zdPoPSEiCYkM5_U2kZilsZKIiQIpEwkqh2T_SCzOwmOxAIA8hjLDC3Hp_RZAIqTwVFwomck0l9lC_P66cYOrpo7a2kTDhnvaTVHP1WjYz_9oU_vBNW5dG2oiyzSMfVCcjcgMdReGKmppzRF11YHn_S4AvnbdDDH1zRS5zrg1z3BL_S_u_TPxxFLj-fnpvhI_bt9_v_4Q33-5-3j99j42SwUQW6yIskIRVoAmLwhStBJLy5gjV4WhlWXmLC3KcmVXBVWWVK6sTcuMpS3xSrw6-u569zCyH3Rbe8NNQx270esSQgqyRBXIFydyXLVc6V1fh10n_S-qALw8AeRDFLanztT-P7dELLHAwL05cn_qhqezLkHP1emtnhvSc0N6rk4fqtN7_e7TzeEZDOKjQQie92eDEJzOcsxT_fPzXRj9VtyoJegC_wK9fZ2w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>907161932</pqid></control><display><type>article</type><title>Photodynamic therapy reduces the histological features of actinic damage and the expression of early oncogenic markers</title><source>MEDLINE</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>Wiley Online Library All Journals</source><creator>Bagazgoitia, L. ; Cuevas Santos, J. ; Juarranz, Á. ; Jaén, P.</creator><creatorcontrib>Bagazgoitia, L. ; Cuevas Santos, J. ; Juarranz, Á. ; Jaén, P.</creatorcontrib><description>Summary
Background Photodynamic therapy (PDT) has been shown to be effective in treating nonmelanoma skin cancer (NMSC), especially actinic keratosis (AK). Moreover, there is sufficient evidence of its effectiveness in preventing the appearance of premalignant and malignant lesions in organ transplant recipients.
Objectives To describe the molecular and genetic changes underlying this preventive effect.
Methods Twenty‐two patients with AK were treated with methyl aminolaevulinate and red light. Biopsies were performed before and 6 weeks after the treatment. Conventional histopathology and immunohistochemistry were carried out.
Results Not only was a reduction in the dysplasia and elastosis observed, but also a decreased expression of Ki‐67 and p53. The abnormal findings did not disappear completely in all cases. The expression of cyclin D1 remained stable.
Conclusions These findings show that PDT has the potential to reduce the histological signs of photoageing. Moreover, the reduction of Ki‐67, a marker of proliferation and of p53, a marker of early skin carcinogenesis, indicates a reversal of the carcinogenic process. On the other hand, the fact that one treatment does not clear dysplasia and expression of p53 completely, and the persistence of cyclin D1, indicate that one single treatment, despite showing good clinical results, is not sufficient to clear completely the signs of chronic actinic damage, and thus the risk of NMSC.</description><identifier>ISSN: 0007-0963</identifier><identifier>EISSN: 1365-2133</identifier><identifier>DOI: 10.1111/j.1365-2133.2011.10270.x</identifier><identifier>PMID: 21615716</identifier><identifier>CODEN: BJDEAZ</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Aged ; Aged, 80 and over ; Aminolevulinic Acid - analogs & derivatives ; Aminolevulinic Acid - therapeutic use ; Biological and medical sciences ; Biomarkers, Tumor - metabolism ; Biopsy ; Carcinogenesis ; Cyclin D - metabolism ; cyclin D1 ; Dermatology ; Dysplasia ; Female ; Humans ; Immunohistochemistry ; Keratosis ; Keratosis, Actinic - drug therapy ; Keratosis, Actinic - metabolism ; Keratosis, Actinic - pathology ; Ki-67 Antigen - metabolism ; Light effects ; Male ; Medical sciences ; Middle Aged ; p53 protein ; Photochemotherapy - methods ; photodynamic therapy ; Photosensitizing Agents - therapeutic use ; Skin cancer ; Tumor Suppressor Protein p53 - metabolism</subject><ispartof>British journal of dermatology (1951), 2011-07, Vol.165 (1), p.144-151</ispartof><rights>2011 The Authors. BJD © 2011 British Association of Dermatologists 2011</rights><rights>2015 INIST-CNRS</rights><rights>2011 The Authors. BJD © 2011 British Association of Dermatologists 2011.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4200-f3daa682a3d03c78a053f139fe373ed8cabfeee65899bfb8adfa272ff596e1f93</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1365-2133.2011.10270.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1365-2133.2011.10270.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>315,781,785,1418,27929,27930,45579,45580</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=24339383$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21615716$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bagazgoitia, L.</creatorcontrib><creatorcontrib>Cuevas Santos, J.</creatorcontrib><creatorcontrib>Juarranz, Á.</creatorcontrib><creatorcontrib>Jaén, P.</creatorcontrib><title>Photodynamic therapy reduces the histological features of actinic damage and the expression of early oncogenic markers</title><title>British journal of dermatology (1951)</title><addtitle>Br J Dermatol</addtitle><description>Summary
Background Photodynamic therapy (PDT) has been shown to be effective in treating nonmelanoma skin cancer (NMSC), especially actinic keratosis (AK). Moreover, there is sufficient evidence of its effectiveness in preventing the appearance of premalignant and malignant lesions in organ transplant recipients.
Objectives To describe the molecular and genetic changes underlying this preventive effect.
Methods Twenty‐two patients with AK were treated with methyl aminolaevulinate and red light. Biopsies were performed before and 6 weeks after the treatment. Conventional histopathology and immunohistochemistry were carried out.
Results Not only was a reduction in the dysplasia and elastosis observed, but also a decreased expression of Ki‐67 and p53. The abnormal findings did not disappear completely in all cases. The expression of cyclin D1 remained stable.
Conclusions These findings show that PDT has the potential to reduce the histological signs of photoageing. Moreover, the reduction of Ki‐67, a marker of proliferation and of p53, a marker of early skin carcinogenesis, indicates a reversal of the carcinogenic process. On the other hand, the fact that one treatment does not clear dysplasia and expression of p53 completely, and the persistence of cyclin D1, indicate that one single treatment, despite showing good clinical results, is not sufficient to clear completely the signs of chronic actinic damage, and thus the risk of NMSC.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Aminolevulinic Acid - analogs & derivatives</subject><subject>Aminolevulinic Acid - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Biomarkers, Tumor - metabolism</subject><subject>Biopsy</subject><subject>Carcinogenesis</subject><subject>Cyclin D - metabolism</subject><subject>cyclin D1</subject><subject>Dermatology</subject><subject>Dysplasia</subject><subject>Female</subject><subject>Humans</subject><subject>Immunohistochemistry</subject><subject>Keratosis</subject><subject>Keratosis, Actinic - drug therapy</subject><subject>Keratosis, Actinic - metabolism</subject><subject>Keratosis, Actinic - pathology</subject><subject>Ki-67 Antigen - metabolism</subject><subject>Light effects</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>p53 protein</subject><subject>Photochemotherapy - methods</subject><subject>photodynamic therapy</subject><subject>Photosensitizing Agents - therapeutic use</subject><subject>Skin cancer</subject><subject>Tumor Suppressor Protein p53 - metabolism</subject><issn>0007-0963</issn><issn>1365-2133</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkU-P0zAQxS0EYrsLXwHlgjgljD3NvwsS7LILaAVIgDhaU2fcpiRxN06g-fY4bSm-2Nb7zdPoPSEiCYkM5_U2kZilsZKIiQIpEwkqh2T_SCzOwmOxAIA8hjLDC3Hp_RZAIqTwVFwomck0l9lC_P66cYOrpo7a2kTDhnvaTVHP1WjYz_9oU_vBNW5dG2oiyzSMfVCcjcgMdReGKmppzRF11YHn_S4AvnbdDDH1zRS5zrg1z3BL_S_u_TPxxFLj-fnpvhI_bt9_v_4Q33-5-3j99j42SwUQW6yIskIRVoAmLwhStBJLy5gjV4WhlWXmLC3KcmVXBVWWVK6sTcuMpS3xSrw6-u569zCyH3Rbe8NNQx270esSQgqyRBXIFydyXLVc6V1fh10n_S-qALw8AeRDFLanztT-P7dELLHAwL05cn_qhqezLkHP1emtnhvSc0N6rk4fqtN7_e7TzeEZDOKjQQie92eDEJzOcsxT_fPzXRj9VtyoJegC_wK9fZ2w</recordid><startdate>201107</startdate><enddate>201107</enddate><creator>Bagazgoitia, L.</creator><creator>Cuevas Santos, J.</creator><creator>Juarranz, Á.</creator><creator>Jaén, P.</creator><general>Blackwell Publishing Ltd</general><general>Wiley-Blackwell</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7TO</scope><scope>H94</scope></search><sort><creationdate>201107</creationdate><title>Photodynamic therapy reduces the histological features of actinic damage and the expression of early oncogenic markers</title><author>Bagazgoitia, L. ; Cuevas Santos, J. ; Juarranz, Á. ; Jaén, P.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4200-f3daa682a3d03c78a053f139fe373ed8cabfeee65899bfb8adfa272ff596e1f93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Aminolevulinic Acid - analogs & derivatives</topic><topic>Aminolevulinic Acid - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Biomarkers, Tumor - metabolism</topic><topic>Biopsy</topic><topic>Carcinogenesis</topic><topic>Cyclin D - metabolism</topic><topic>cyclin D1</topic><topic>Dermatology</topic><topic>Dysplasia</topic><topic>Female</topic><topic>Humans</topic><topic>Immunohistochemistry</topic><topic>Keratosis</topic><topic>Keratosis, Actinic - drug therapy</topic><topic>Keratosis, Actinic - metabolism</topic><topic>Keratosis, Actinic - pathology</topic><topic>Ki-67 Antigen - metabolism</topic><topic>Light effects</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>p53 protein</topic><topic>Photochemotherapy - methods</topic><topic>photodynamic therapy</topic><topic>Photosensitizing Agents - therapeutic use</topic><topic>Skin cancer</topic><topic>Tumor Suppressor Protein p53 - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bagazgoitia, L.</creatorcontrib><creatorcontrib>Cuevas Santos, J.</creatorcontrib><creatorcontrib>Juarranz, Á.</creatorcontrib><creatorcontrib>Jaén, P.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>British journal of dermatology (1951)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bagazgoitia, L.</au><au>Cuevas Santos, J.</au><au>Juarranz, Á.</au><au>Jaén, P.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Photodynamic therapy reduces the histological features of actinic damage and the expression of early oncogenic markers</atitle><jtitle>British journal of dermatology (1951)</jtitle><addtitle>Br J Dermatol</addtitle><date>2011-07</date><risdate>2011</risdate><volume>165</volume><issue>1</issue><spage>144</spage><epage>151</epage><pages>144-151</pages><issn>0007-0963</issn><eissn>1365-2133</eissn><coden>BJDEAZ</coden><abstract>Summary
Background Photodynamic therapy (PDT) has been shown to be effective in treating nonmelanoma skin cancer (NMSC), especially actinic keratosis (AK). Moreover, there is sufficient evidence of its effectiveness in preventing the appearance of premalignant and malignant lesions in organ transplant recipients.
Objectives To describe the molecular and genetic changes underlying this preventive effect.
Methods Twenty‐two patients with AK were treated with methyl aminolaevulinate and red light. Biopsies were performed before and 6 weeks after the treatment. Conventional histopathology and immunohistochemistry were carried out.
Results Not only was a reduction in the dysplasia and elastosis observed, but also a decreased expression of Ki‐67 and p53. The abnormal findings did not disappear completely in all cases. The expression of cyclin D1 remained stable.
Conclusions These findings show that PDT has the potential to reduce the histological signs of photoageing. Moreover, the reduction of Ki‐67, a marker of proliferation and of p53, a marker of early skin carcinogenesis, indicates a reversal of the carcinogenic process. On the other hand, the fact that one treatment does not clear dysplasia and expression of p53 completely, and the persistence of cyclin D1, indicate that one single treatment, despite showing good clinical results, is not sufficient to clear completely the signs of chronic actinic damage, and thus the risk of NMSC.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>21615716</pmid><doi>10.1111/j.1365-2133.2011.10270.x</doi><tpages>8</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0007-0963 |
ispartof | British journal of dermatology (1951), 2011-07, Vol.165 (1), p.144-151 |
issn | 0007-0963 1365-2133 |
language | eng |
recordid | cdi_proquest_miscellaneous_907161932 |
source | MEDLINE; Oxford University Press Journals All Titles (1996-Current); Wiley Online Library All Journals |
subjects | Aged Aged, 80 and over Aminolevulinic Acid - analogs & derivatives Aminolevulinic Acid - therapeutic use Biological and medical sciences Biomarkers, Tumor - metabolism Biopsy Carcinogenesis Cyclin D - metabolism cyclin D1 Dermatology Dysplasia Female Humans Immunohistochemistry Keratosis Keratosis, Actinic - drug therapy Keratosis, Actinic - metabolism Keratosis, Actinic - pathology Ki-67 Antigen - metabolism Light effects Male Medical sciences Middle Aged p53 protein Photochemotherapy - methods photodynamic therapy Photosensitizing Agents - therapeutic use Skin cancer Tumor Suppressor Protein p53 - metabolism |
title | Photodynamic therapy reduces the histological features of actinic damage and the expression of early oncogenic markers |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-13T13%3A27%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Photodynamic%20therapy%20reduces%20the%20histological%20features%20of%20actinic%20damage%20and%20the%20expression%20of%20early%20oncogenic%20markers&rft.jtitle=British%20journal%20of%20dermatology%20(1951)&rft.au=Bagazgoitia,%20L.&rft.date=2011-07&rft.volume=165&rft.issue=1&rft.spage=144&rft.epage=151&rft.pages=144-151&rft.issn=0007-0963&rft.eissn=1365-2133&rft.coden=BJDEAZ&rft_id=info:doi/10.1111/j.1365-2133.2011.10270.x&rft_dat=%3Cproquest_pubme%3E907161932%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=907161932&rft_id=info:pmid/21615716&rfr_iscdi=true |